Photo of Katy Rezvani taken from mdanderson.org
Jan 21, 2024, 18:52
Katy Rezvani: Our paper on our Phase I / II trial with cord blood CAR19/IL15 NK cells is published
Katy Rezvani, Chief of Section of Cellular Therapy, Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Centre, shared on X:
A
“Please check out our paper published in Nature Medicine on our Phase I / II trial with cord blood CAR19/IL15 NK cells. We report promising 1 year PF and OS rates of 32% and 68% in patients with relapsed / refractory B cell malignancies (with a median of 4 prior lines of treatment).
We show that selection of cord blood donors is crucial – units preserved within 24hrs and with low red cell content led to PFS and OS rates of 69% and 94%.”
A